1. Home
  2. EMBC vs IMNM Comparison

EMBC vs IMNM Comparison

Compare EMBC & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EMBC
  • IMNM
  • Stock Information
  • Founded
  • EMBC 1924
  • IMNM 2006
  • Country
  • EMBC United States
  • IMNM United States
  • Employees
  • EMBC N/A
  • IMNM N/A
  • Industry
  • EMBC Medical/Dental Instruments
  • IMNM Medicinal Chemicals and Botanical Products
  • Sector
  • EMBC Health Care
  • IMNM Health Care
  • Exchange
  • EMBC Nasdaq
  • IMNM Nasdaq
  • Market Cap
  • EMBC 726.8M
  • IMNM 748.3M
  • IPO Year
  • EMBC N/A
  • IMNM 2020
  • Fundamental
  • Price
  • EMBC $10.39
  • IMNM $8.77
  • Analyst Decision
  • EMBC Hold
  • IMNM Strong Buy
  • Analyst Count
  • EMBC 3
  • IMNM 5
  • Target Price
  • EMBC $17.00
  • IMNM $26.40
  • AVG Volume (30 Days)
  • EMBC 688.2K
  • IMNM 1.1M
  • Earning Date
  • EMBC 08-08-2025
  • IMNM 08-11-2025
  • Dividend Yield
  • EMBC 5.72%
  • IMNM N/A
  • EPS Growth
  • EMBC N/A
  • IMNM N/A
  • EPS
  • EMBC 0.89
  • IMNM N/A
  • Revenue
  • EMBC $1,079,500,000.00
  • IMNM $10,938,000.00
  • Revenue This Year
  • EMBC N/A
  • IMNM N/A
  • Revenue Next Year
  • EMBC N/A
  • IMNM $310.65
  • P/E Ratio
  • EMBC $11.75
  • IMNM N/A
  • Revenue Growth
  • EMBC N/A
  • IMNM N/A
  • 52 Week Low
  • EMBC $9.20
  • IMNM $5.15
  • 52 Week High
  • EMBC $21.48
  • IMNM $16.81
  • Technical
  • Relative Strength Index (RSI)
  • EMBC 50.88
  • IMNM 49.38
  • Support Level
  • EMBC $9.97
  • IMNM $8.60
  • Resistance Level
  • EMBC $10.87
  • IMNM $9.27
  • Average True Range (ATR)
  • EMBC 0.45
  • IMNM 0.46
  • MACD
  • EMBC 0.14
  • IMNM -0.03
  • Stochastic Oscillator
  • EMBC 71.47
  • IMNM 44.57

About EMBC Embecta Corp.

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.

About IMNM Immunome Inc.

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.

Share on Social Networks: